LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. has filed a resale registration statement covering up to 5,502,402 shares of common stock that may be sold from time to time by Sermonix Pharmaceuticals and its permitted transferees. These shares are issuable upon exercise of a pre-funded warrant that Sermonix received in connection with a December 2025 license agreement granting LeonaBio exclusive rights to develop and commercialize lasofoxifene in certain territories.
LeonaBio will not receive any proceeds from Sermonix’s resale of the registered shares, but would receive up to approximately $5,502 in gross proceeds if the warrant is fully exercised for cash at an exercise price of $0.001 per share, which it plans to use for working capital and to advance lasofoxifene and other pipeline drug candidates. As of December 31, 2025, 9,335,913 shares of common stock were outstanding, separate from the shares covered by this resale registration.
LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately $146,249,987 from cash exercise of 23,031,494 common warrants at $6.35 per share. The company plans to use any such warrant exercise proceeds for working capital and to advance its drug pipeline, including lead candidates lasofoxifene and ATH-1105. Its common stock trades on Nasdaq under the symbol “LONA.”
Perceptive Advisors and its affiliates report a 19.99% beneficial stake in LeonaBio, Inc. common stock, totaling 1,859,322 shares. These shares are held through Perceptive Advisors LLC, its founder Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. and Perceptive Xontogeny Venture Fund II, LP, with the Master Fund holding 1,529,566 shares (16.4%) and PXV II holding 329,756 shares (3.5%).
The ownership percentages are based on 9,300,434 shares of LeonaBio common stock outstanding, which includes 3,943,887 shares outstanding as of November 5, 2025 and 5,356,547 shares issued in a private placement. The filing also notes a 19.99% beneficial ownership limitation: Joseph Edelman’s vested stock options and the warrants and pre-funded warrants held by the Master Fund and PXV II cannot be exercised to the extent such exercise would push the group’s beneficial ownership above 19.99%, and as of this amendment those warrants and pre-funded warrants are not exercisable under that limitation.